source
- Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trialLatigo Biotherapeutics announced that its experimental non-opioid analgesic demonstrated a reduction in acute pain in a Phase 2b clinical trial. The study results suggest the candidate may offer a…
- FDA advisory panel reviews Replimune's experimental melanoma therapy RP1STAT is live-blogging an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting that convened on Thursday to examine Replimune's engineered viral immunotherapy RP1 for melanoma. The p…